NO177590C - Analogifremgangsmåte for fremstilling av terapeutisk aktive cykliske aminforbindelser - Google Patents
Analogifremgangsmåte for fremstilling av terapeutisk aktive cykliske aminforbindelserInfo
- Publication number
- NO177590C NO177590C NO882696A NO882696A NO177590C NO 177590 C NO177590 C NO 177590C NO 882696 A NO882696 A NO 882696A NO 882696 A NO882696 A NO 882696A NO 177590 C NO177590 C NO 177590C
- Authority
- NO
- Norway
- Prior art keywords
- chr22
- phenyl
- substd
- alkyl
- lower alkyl
- Prior art date
Links
- -1 Cyclic Amine Compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000006360 carbonyl amino methylene group Chemical group [H]N(C([*:1])=O)C([H])([H])[*:2] 0.000 abstract 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 abstract 1
- 150000003950 cyclic amides Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000005412 pyrazyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S152/00—Resilient tires and wheels
- Y10S152/90—Tread pattern having no blocks and having circumferential ribs defined by zig-zag circumferential grooves
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Lubricants (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cephalosporin Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15505887 | 1987-06-22 |
Publications (4)
Publication Number | Publication Date |
---|---|
NO882696D0 NO882696D0 (no) | 1988-06-17 |
NO882696L NO882696L (no) | 1988-12-23 |
NO177590B NO177590B (no) | 1995-07-10 |
NO177590C true NO177590C (no) | 1995-10-18 |
Family
ID=15597749
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO882696A NO177590C (no) | 1987-06-22 | 1988-06-17 | Analogifremgangsmåte for fremstilling av terapeutisk aktive cykliske aminforbindelser |
NO1998015C NO1998015I1 (no) | 1987-06-22 | 1998-05-12 | Donepezil |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO1998015C NO1998015I1 (no) | 1987-06-22 | 1998-05-12 | Donepezil |
Country Status (25)
Country | Link |
---|---|
US (2) | US4895841A (zh) |
EP (5) | EP0579263B1 (zh) |
JP (3) | JP2578475B2 (zh) |
KR (1) | KR910003618B1 (zh) |
CN (3) | CN1024547C (zh) |
AT (4) | ATE134618T1 (zh) |
AU (1) | AU627151B2 (zh) |
CA (2) | CA1338808C (zh) |
CY (3) | CY1940A (zh) |
DD (1) | DD283377A5 (zh) |
DE (5) | DE19775093I1 (zh) |
DK (3) | DK172337B1 (zh) |
ES (4) | ES2083359T3 (zh) |
FI (3) | FI95572C (zh) |
GR (2) | GR3019142T3 (zh) |
HK (1) | HK216396A (zh) |
HU (3) | HU214592B (zh) |
LU (1) | LU90221I2 (zh) |
NO (2) | NO177590C (zh) |
NZ (1) | NZ224970A (zh) |
PH (1) | PH26315A (zh) |
PT (1) | PT87783B (zh) |
RU (1) | RU2009128C1 (zh) |
SG (1) | SG50439A1 (zh) |
ZA (1) | ZA884338B (zh) |
Families Citing this family (323)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2832979B2 (ja) * | 1988-02-15 | 1998-12-09 | 武田薬品工業株式会社 | 不飽和カルボン酸アミド誘導体 |
WO1990006303A1 (en) * | 1988-12-02 | 1990-06-14 | Pfizer Inc. | Arylpiperidine derivatives |
JP2777159B2 (ja) | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
JP2969359B2 (ja) * | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
US5225402A (en) * | 1989-02-10 | 1993-07-06 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JP2931986B2 (ja) * | 1989-02-17 | 1999-08-09 | 武田薬品工業株式会社 | アラルキルアミン誘導体 |
US5250528A (en) * | 1989-08-02 | 1993-10-05 | Fujisawa Pharmaceutical Co., Ltd. | New aminopiperazine derivatives |
US5109002A (en) * | 1989-09-08 | 1992-04-28 | Du Pont Merck Pharmaceutical Company | Antipsychotic 1-cycloalkylpiperidines |
US5356906A (en) * | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
CA2069318A1 (en) * | 1989-10-27 | 1991-04-28 | Engelbert Ciganek | (n-phthalimidoalkyl) piperidines |
AU636921B2 (en) * | 1989-10-30 | 1993-05-13 | Syntex (U.S.A.) Inc. | Benzylpyrrolidine derivatives as dopamine agonists |
US5206240A (en) * | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
US5032604A (en) * | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
US5032598A (en) * | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
US5215989A (en) * | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
US5112824A (en) * | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
CA2071897A1 (en) * | 1989-12-28 | 1991-06-29 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
US5428043A (en) * | 1990-02-08 | 1995-06-27 | Pfizer Inc. | Tricyclic-cyclic amines as novel cholinesterase inhibitors |
FR2659323B1 (fr) * | 1990-03-07 | 1992-06-12 | Synthelabo | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. |
US5272157A (en) * | 1990-03-07 | 1993-12-21 | Synthelabo | Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application |
US5116846A (en) * | 1990-03-28 | 1992-05-26 | Du Pont Merck Pharmaceutical Company | N-aralkyl piperidine derivatives as psychotropic drugs |
US5173209A (en) * | 1990-05-10 | 1992-12-22 | Cyprus Foote Mineral Company | Stable lithium cycloalkylimides |
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
KR100211713B1 (ko) * | 1990-06-01 | 1999-08-02 | 슈테펜 엘. 네스비트 | (+)-알파-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 |
JP2807577B2 (ja) * | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
DE69123090D1 (de) * | 1990-07-06 | 1996-12-19 | Yoshitomi Pharmaceutical | Kondensierte Thiophenverbindungen und deren Verwendung |
FR2664592B1 (fr) * | 1990-07-10 | 1994-09-02 | Adir | Nouveaux derives de la piperidine, de la tetrahydropyridine et de la pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
TW199153B (zh) * | 1990-08-07 | 1993-02-01 | Dtsuka Seiyaku Kk | |
US5190951A (en) * | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US5240934A (en) * | 1990-10-19 | 1993-08-31 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
TW197435B (zh) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
DE4104870A1 (de) * | 1991-02-17 | 1992-08-27 | Bayer Ag | Verwendung von 3,(4)-substituierten pyrrolidinen als katalysatoren fuer das polyisocyanatpolyadditionsverfahren, verfahren zu ihrer herstellung sowie verfahren zur herstellung von polyurethan(harnstoff)en |
US5162341A (en) * | 1991-02-22 | 1992-11-10 | Du Pont Merck Pharmaceutical Company | Use of sigma receptor antagonists for treatment of amphetamine abuse |
DE69232907T2 (de) * | 1991-03-28 | 2003-05-15 | Eisai Co., Ltd. | Neue heterocyclische/cyclische amine |
US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
FR2676226B1 (fr) * | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux intermediaires pour la synthese de composes dialkylenepiperidino. |
FR2676225B1 (fr) * | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux intermediaires pour la synthese de composes dialkylenepiperidino. |
US5556857A (en) * | 1991-05-08 | 1996-09-17 | Otsuka Pharmaceutical Co., Ltd. | Disturbance-of-consciousness improving agent |
CA2067475C (en) * | 1991-05-08 | 2000-10-10 | Yasuo Oshiro | Carbostyril derivatives and their use |
FR2677019B1 (fr) * | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
US5106856A (en) * | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
EP0535496A1 (en) | 1991-09-25 | 1993-04-07 | Hoechst-Roussel Pharmaceuticals Incorporated | (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments |
TW263504B (zh) * | 1991-10-03 | 1995-11-21 | Pfizer | |
SE9103752D0 (sv) * | 1991-12-18 | 1991-12-18 | Astra Ab | New compounds |
US5462934A (en) * | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
EP0567090B1 (en) * | 1992-04-24 | 2000-07-26 | Takeda Chemical Industries, Ltd. | Benzoxazepine derivatives as cholinesterase inhibitors |
AU672034B2 (en) * | 1992-10-05 | 1996-09-19 | Ube Industries, Ltd. | Pyrimidine compound |
US5914328A (en) * | 1992-10-09 | 1999-06-22 | Abbott Laboratories | Heterocyclic ether compounds useful in controlling neurotransmitter release |
US5948793A (en) * | 1992-10-09 | 1999-09-07 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release |
TW248556B (zh) * | 1993-01-18 | 1995-06-01 | Takeda Pharm Industry Co | |
CA2136999C (en) * | 1993-04-07 | 2004-05-11 | Takafumi Fujioka | Peripheral vasodilating agent containing piperidine derivative as active ingredient |
US5459151A (en) * | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
EP0714292A4 (en) * | 1993-06-23 | 1996-10-09 | Cambridge Neuroscience Inc | SIGMA RECEPTOR LIGANDS AND THEIR USE |
DK0637586T3 (da) * | 1993-08-05 | 1999-12-06 | Hoechst Marion Roussel Inc | 2-(Piperidin-4-yl, pyridin-4-yl og tetrahydropyridin-4-yl)-benzofuran-7-carbamatderivater, deres fremstilling og anvendelse |
GB9319534D0 (en) * | 1993-09-22 | 1993-11-10 | Boots Co Plc | Therapeutic agents |
ES2108484T3 (es) * | 1993-11-30 | 1997-12-16 | Pfizer | Procedimiento para la preparacion de una tetralona asimetrica. |
DE4439822A1 (de) | 1994-11-08 | 1996-08-29 | Bayer Ag | Verfahren zur Herstellung von Benzyl-piperidylmethyl-indanonen |
US6214994B1 (en) | 1997-04-21 | 2001-04-10 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-piperazin-1′-yl propanones |
US5658909A (en) | 1994-11-17 | 1997-08-19 | Molecular Geriatrics Corporation | Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease |
US5859295A (en) * | 1994-12-05 | 1999-01-12 | University Of Kentucky Research Foundation | Canavanine analogs and their use as chemotherapeutic agents |
AU4483896A (en) * | 1995-01-18 | 1996-08-07 | Bayer Aktiengesellschaft | N-substituted 1-acylaminoalkyl piperidines for treatment of cerebral disorders and depressions |
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5703239A (en) * | 1995-06-02 | 1997-12-30 | Bristol-Myers Squibb Company | Indanylpiperidines as melatonergic agents |
US20100210590A1 (en) * | 1995-09-27 | 2010-08-19 | Northwestern University | Compositions and treatments for seizure-related disorders |
SK75498A3 (en) * | 1995-12-15 | 1999-08-06 | Pfizer | Processes and intermediates for preparing 1-benzyl-4-((5,6- -dimethoxy-1-indanon)-2-yl)methylpiperidine |
US6025355A (en) | 1997-05-19 | 2000-02-15 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
US5629325A (en) * | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
US6437138B1 (en) | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
DK1019374T3 (da) * | 1996-06-07 | 2003-04-07 | Eisai Co Ltd | Polymorfe og Donepezil-hydrochlorid og fremstillingsfremgangsmåde |
TW513409B (en) * | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
WO1997046526A1 (en) * | 1996-06-07 | 1997-12-11 | Eisai Co., Ltd. | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
US5935958A (en) * | 1996-07-01 | 1999-08-10 | Schering Corporation | Muscarinic antagonists |
FR2750991A1 (fr) * | 1996-07-12 | 1998-01-16 | Pf Medicament | Nouveaux benzodioxannes et 1-(2h)-benzopyrannes, leur preparation et leur utilisation comme medicament |
US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
US6756389B2 (en) | 1996-08-09 | 2004-06-29 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
US5977138A (en) * | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
WO1998007703A1 (fr) * | 1996-08-22 | 1998-02-26 | Meiji Seika Kaisha, Ltd. | Derives quinoleine et agent psychotrope |
FR2752732B1 (fr) | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
US6133253A (en) * | 1996-12-10 | 2000-10-17 | Abbott Laboratories | 3-Pyridyl enantiomers and their use as analgesics |
US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
CA2282654C (en) * | 1997-03-03 | 2009-02-03 | Eisai Co., Ltd. | Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder |
WO1998056380A1 (en) * | 1997-06-11 | 1998-12-17 | Alcon Laboratories, Inc. | Method to reverse mydriasis |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
US5945421A (en) * | 1997-08-11 | 1999-08-31 | Warner-Lambert Company | Dopamine D4 receptor antagonists |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
US6339087B1 (en) | 1997-08-18 | 2002-01-15 | Syntex (U.S.A.) Llc | Cyclic amine derivatives-CCR-3 receptor antagonists |
AU9454098A (en) | 1997-09-24 | 1999-04-12 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
ATE260896T1 (de) * | 1997-12-05 | 2004-03-15 | Eisai Co Ltd | Donepezil polykristalle und verfharen zu ihrer herstellung |
DE69924467T2 (de) | 1998-01-16 | 2006-02-16 | Eisai Co., Ltd. | Verfahren zur herstellung von donepezilderivaten |
US6713627B2 (en) | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6066636A (en) * | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
US6262081B1 (en) | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
IL125809A (en) | 1998-08-17 | 2005-08-31 | Finetech Lab Ltd | Process and intermediates for production of donepezil and related compounds |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US20020177593A1 (en) | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
HUP0104493A3 (en) * | 1998-09-30 | 2002-12-28 | Takeda Pharmaceutical | Drugs for improving vesical excretory strength |
IL143226A0 (en) * | 1998-11-20 | 2002-04-21 | Hoffmann La Roche | Pyrrolidine derivatives-ccr-3 receptor antagonists |
JP3421323B2 (ja) | 1998-11-20 | 2003-06-30 | エフ.ホフマン−ラ ロシュ アーゲー | ピペリジンccr−3受容体拮抗薬 |
CA2355296A1 (en) * | 1998-12-11 | 2000-06-15 | American Biogenetic Sciences, Inc. | Substituted nitrogen heterocyclic compounds and therapeutic uses thereof |
DE60014043T2 (de) | 1999-03-03 | 2005-09-29 | Eisai Co., Ltd. | Flouride von 4-substituierten piperidin-derivaten |
US6277866B1 (en) * | 1999-03-03 | 2001-08-21 | Eisai Co., Ltd. | 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine |
US6833370B1 (en) | 1999-05-21 | 2004-12-21 | Abbott Laboratories | Heterocycle substituted aminoazacycles useful as central nervous system agents |
GB9914486D0 (en) | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
GB9917406D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
WO2001016105A1 (fr) | 1999-09-01 | 2001-03-08 | Eisai Co., Ltd. | Derives de piperidine 4-substituee |
GB0002100D0 (en) | 2000-01-28 | 2000-03-22 | Novartis Ag | Organic compounds |
US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
PT1311272E (pt) | 2000-03-03 | 2007-02-28 | Eisai R&D Man Co Ltd | Novos métodos utilizando inibidores de colinesterase |
EP1764101A1 (en) * | 2000-03-03 | 2007-03-21 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments |
US6706741B2 (en) | 2000-04-13 | 2004-03-16 | Eisai Co., Ltd. | Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts |
EP1284729A4 (en) * | 2000-04-13 | 2007-12-19 | Mayo Foundation | REDUCTION AGENTS OF A (BETA) 42 |
US6906083B2 (en) | 2000-06-21 | 2005-06-14 | Eisai Co., Ltd. | 4-substituted piperidine compound |
AU2001267899A1 (en) * | 2000-07-03 | 2002-01-14 | Eisai Co. Ltd. | Pharmaceutical compositions for controlling intraocular pressure |
CN1317276C (zh) * | 2000-09-29 | 2007-05-23 | 中国科学院上海药物研究所 | 一类吲哚基哌啶类化合物及其制备方法和用途 |
AU2002224046A1 (en) * | 2000-12-07 | 2002-06-18 | Fujisawa Pharmaceutical Co. Ltd. | Nootropic effect enhancer |
EP1390034A4 (en) * | 2001-04-03 | 2005-07-13 | Merck & Co Inc | NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS |
CA2447884A1 (en) * | 2001-05-25 | 2002-12-05 | Schering Corporation | Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
US20030060423A1 (en) * | 2001-08-30 | 2003-03-27 | Plata-Salaman Carlos R. | Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors |
WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
US20050226934A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Inclusion complexes of active compounds in acrylate (co)polymers and methods for their production |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
AU2002340232A1 (en) * | 2001-10-17 | 2003-04-28 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
GB0126378D0 (en) * | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
WO2003061658A1 (fr) * | 2002-01-22 | 2003-07-31 | Eisai Co., Ltd. | Agent liant de récepteur sigma contenant un dérivé d'indanone |
AU2003207184B2 (en) * | 2002-02-07 | 2008-02-14 | Eisai R And D Management Co., Ltd. | Hair growth stimulants, percutaneous preparations and method of stimulating hair growth |
EP1496913A4 (en) * | 2002-03-15 | 2007-10-31 | Samaritan Pharmaceuticals Inc | NEUROPROTECTIVE PHARMACEUTICAL SPIROSTENOL COMPOSITIONS |
ES2297141T3 (es) * | 2002-03-29 | 2008-05-01 | EISAI R&D MANAGEMENT CO., LTD. | Derivados de (1-indanona)-(1,2,3,6-tetrahidropiridina). |
US20040033986A1 (en) | 2002-05-17 | 2004-02-19 | Protopopova Marina Nikolaevna | Anti tubercular drug: compositions and methods |
CN101404986B (zh) | 2002-05-17 | 2011-09-28 | 赛奎拉公司 | 用于诊断和治疗感染性疾病的组合物和制药方法 |
NZ537090A (en) | 2002-06-14 | 2006-02-24 | Toyama Chemical Co Ltd | Medicinal compositions improving brain function and method for improving brain function |
IL150509A (en) * | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
CA2490470A1 (en) * | 2002-07-02 | 2004-01-15 | Schering Corporation | Pyrazole urea neuropeptide y y5 receptor antagonists |
US7148354B2 (en) * | 2002-07-24 | 2006-12-12 | Dr. Reddy's Laboratories Limited | Process for preparation of donepezil |
IL150982A (en) * | 2002-07-30 | 2007-02-11 | Ori Lerman | Process for making Donafzil |
GB0218326D0 (en) * | 2002-08-07 | 2002-09-11 | Glaxo Group Ltd | Compounds |
JP2006506378A (ja) * | 2002-10-24 | 2006-02-23 | メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン | 1−アミノシクロヘキサン誘導体及びアセチルコリンエステラーゼ阻害薬を用いる併用療法 |
US20060014801A1 (en) * | 2002-11-22 | 2006-01-19 | The Johns Hopkins University | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
JP2004189706A (ja) * | 2002-12-13 | 2004-07-08 | Eisai Co Ltd | 高度アルツハイマー型痴呆治療剤 |
WO2004071431A2 (en) * | 2003-02-05 | 2004-08-26 | Myriad Genetics, Inc. | Method and composition for treating neurodegenerative disorders |
US20080057491A1 (en) * | 2003-02-07 | 2008-03-06 | Mckee Patrick A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use |
US6649765B1 (en) | 2003-02-12 | 2003-11-18 | Usv Limited, Bsd Marg. | Process for the preparation of 1-benzyl-4(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCL) |
US6953856B2 (en) * | 2003-02-12 | 2005-10-11 | Usv, Limited | Process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (Donepezil HCI) |
US20050288330A1 (en) * | 2004-06-29 | 2005-12-29 | Avinash Naidu | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) |
US7439365B2 (en) * | 2003-11-17 | 2008-10-21 | Usv, Ltd. | Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil) |
US7186842B2 (en) * | 2003-02-12 | 2007-03-06 | Usv, Ltd. | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof |
CN100422148C (zh) * | 2003-02-27 | 2008-10-01 | 天津药物研究院 | 工业化生产盐酸多奈哌齐的工艺方法 |
US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
DE602004029993D1 (de) * | 2003-02-27 | 2010-12-23 | Eisai R&D Man Co Ltd | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit |
US20060009433A1 (en) * | 2003-03-14 | 2006-01-12 | Zhi-Xing Yao | Neuroprotective spirostenol pharmaceutical compositions |
EP1608371A1 (en) * | 2003-03-21 | 2005-12-28 | Ranbaxy Laboratories, Ltd. | Process for the preparation of donepezil and derivatives thereof |
US20040229914A1 (en) * | 2003-04-02 | 2004-11-18 | Dr. Reddy's Laboratories Limited | Novel crystalline form-VI of donepezil hydrochloride and process for the preparation thereof |
AU2003230195A1 (en) * | 2003-04-02 | 2004-10-25 | Hetero Drugs Limited | A novel process for amorphous form of donepezil hydrochloride |
WO2004092137A1 (en) | 2003-04-16 | 2004-10-28 | Hetero Drugs Limited | Novel crystalline forms of donepezil hydrochloride |
EP1654230A1 (en) * | 2003-07-01 | 2006-05-10 | Hetero Drugs Limited | Preparation of intermediates for acetyl cholinesterase inhibitors |
WO2005065069A2 (en) * | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease |
GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
JP5005343B2 (ja) * | 2003-07-25 | 2012-08-22 | エフ.ホフマン−ラ ロシュ アーゲー | 急性及び/又は慢性神経障害の治療のためのmGluR2アンタゴニストとAChEインヒビターの併用 |
CN1280273C (zh) | 2003-11-05 | 2006-10-18 | 天津和美生物技术有限公司 | 合成多奈哌齐及其衍生物的方法 |
ATE473967T1 (de) * | 2003-11-26 | 2010-07-15 | Pfizer Prod Inc | Aminopyrazolderivate als gsk-3-inhibitoren |
US20050232990A1 (en) * | 2003-12-31 | 2005-10-20 | Garth Boehm | Donepezil formulations |
CN1300112C (zh) * | 2004-01-06 | 2007-02-14 | 浙江大学 | N-苄基-4-哌啶基甲醛的合成方法 |
WO2005072713A2 (en) | 2004-01-27 | 2005-08-11 | The Feinstein Institute For Medical Research | Cholinesterase inhibitors for treating inflammation |
MY142362A (en) * | 2004-01-29 | 2010-11-30 | Otsuka Pharma Co Ltd | Pharmaceutical composition for promoting angiogenesis |
WO2005087226A1 (en) * | 2004-03-05 | 2005-09-22 | Eisai Co., Ltd. | Cadasil treatment with cholinesterase inhibitors |
US20070293538A1 (en) * | 2004-04-13 | 2007-12-20 | Myriad Genetics, Incorporated | Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders |
WO2005105742A1 (ja) * | 2004-04-28 | 2005-11-10 | Eisai R&D Management Co., Ltd. | 1-ベンジル-4-[(5,6-ジメトキシ-1-インダノン)-2-イル]メチルピペリジンおよびその塩酸塩の製造法 |
CN1946906A (zh) * | 2004-04-29 | 2007-04-11 | 吉斯通护岸系统股份有限公司 | 用于墙、护墙和类似物的饰面 |
AU2005244867A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
US20080045500A1 (en) * | 2004-07-01 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Nerve Regeneration Stimulator |
WO2006015338A2 (en) * | 2004-07-30 | 2006-02-09 | Dr. Reddy's Laboratories Ltd. | Crystalline form of donepezil hydrochloride |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020853A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
HUP0401850A3 (en) * | 2004-09-15 | 2008-03-28 | Egis Gyogyszergyar Nyilvanosan | Donepezil salts for producing pharmaceutical composition |
US7718674B2 (en) | 2004-09-27 | 2010-05-18 | Bridge Pharma, Inc. | Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine |
US7592459B2 (en) * | 2004-09-29 | 2009-09-22 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
US9186345B2 (en) * | 2004-10-12 | 2015-11-17 | Hakon Hakonarson | Method of treating skin diseases |
GB2419093A (en) * | 2004-10-12 | 2006-04-19 | Ernir Snorrason | Acetylcholinesterase inhibitors for the treatment of skin |
EP1812007B1 (en) * | 2004-11-02 | 2011-09-07 | Northwestern University | Pyridazine compounds and methods |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
US8058291B2 (en) * | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
KR20070084455A (ko) * | 2004-11-23 | 2007-08-24 | 워너-램버트 캄파니 엘엘씨 | 지질혈증 치료용 hmg co-a 환원효소 억제제로서의7-(2h-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체 |
US20060122226A1 (en) | 2004-12-08 | 2006-06-08 | Itai Adin | Crystalline forms of Donepezil base |
US8124783B2 (en) * | 2004-12-30 | 2012-02-28 | Jubilant Organosys Limited | Process for producing 1-benzyl-4-[5,6-dimethoxy-1-indanon-2-yl)methyl] piperidine or its salt thereof via novel intermediate |
JP5731094B2 (ja) | 2005-02-11 | 2015-06-10 | スティーブン・ウィルスStephen WILLS | アセチルコリンエステラーゼ阻害剤による微小血管系疾患の治療 |
EP1858848A1 (en) * | 2005-03-17 | 2007-11-28 | Synthon B.V. | Process for making crystalline donepezil hydrochloride monohydrate |
AU2006232517A1 (en) * | 2005-04-04 | 2006-10-12 | Eisai R&D Management Co., Ltd. | Dihydropyridine compounds and compositions for headaches |
US20080188510A1 (en) * | 2005-05-23 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Novel methods using zonisamide |
US20070015832A1 (en) * | 2005-07-14 | 2007-01-18 | Myriad Genetics, Incorporated | Methods of treating overactive bladder and urinary incontinence |
US20090171094A1 (en) * | 2005-07-15 | 2009-07-02 | Kazuhide Ashizawa | 1-benzyl-4-[(5, 6-dimethoxy- 1- indanon)- 2- yl]-methyl piperidine p-toluenesulfonate or crystal thereof |
US20070042034A1 (en) * | 2005-07-22 | 2007-02-22 | Myriad Genetics, Incorporated | High drug load formulations and dosage forms |
JP5001151B2 (ja) * | 2005-07-25 | 2012-08-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 1−ベンジル−4−[(5,6−ジメトキシ−1−インダノン)−2−イリデン]メチルピペリジンの製造法 |
JP2009502917A (ja) * | 2005-07-28 | 2009-01-29 | テイコク ファーマ ユーエスエー インコーポレーテッド | ゲル化ドネペジル組成物および該組成物の製法並びに使用法 |
CN100436416C (zh) * | 2005-07-29 | 2008-11-26 | 西南合成制药股份有限公司 | 盐酸多奈哌齐合成工艺 |
GB0515803D0 (en) | 2005-07-30 | 2005-09-07 | Pliva Hrvatska D O O | Intermediate compounds |
EP1939178B1 (en) * | 2005-10-14 | 2010-11-24 | Eisai R&D Management Co., Ltd. | Process for producing 1-benzyl-4-[(5,6-dimethoxy-1indanon)-2-yl]methylpiperidine or hydrochloride thereof |
JPWO2007043440A1 (ja) * | 2005-10-14 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 1−ベンジル−4−[(5,6−ジメトキシ−1−インダノン)−2−イル]メチルピペリジンまたはその塩酸塩の製造法 |
EP2612854B1 (en) | 2005-10-25 | 2015-04-29 | Shionogi&Co., Ltd. | Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors |
JP2008280248A (ja) * | 2005-11-02 | 2008-11-20 | Eisai R & D Management Co Ltd | アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ |
AR057910A1 (es) | 2005-11-18 | 2007-12-26 | Synthon Bv | Proceso para preparar donepezilo |
HU227474B1 (en) * | 2005-12-20 | 2011-07-28 | Richter Gedeon Nyrt | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. |
ES2354737T3 (es) * | 2006-01-04 | 2011-03-17 | Cipla Limited | Procedimiento y producto intermedio para la preparación de donepezylo. |
US7994328B2 (en) | 2006-02-16 | 2011-08-09 | Aurobindo Pharma Ltd. | Process for the preparation of donepezil hydrochloride |
EP1988077A4 (en) | 2006-02-23 | 2009-09-02 | Shionogi & Co | NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS |
WO2007108011A2 (en) * | 2006-03-20 | 2007-09-27 | Ind-Swift Laboratories Limited | Process for the preparation of highly pure donepezil |
CA2650711A1 (en) * | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
WO2007131804A1 (en) | 2006-05-17 | 2007-11-22 | Synthon B.V. | Tablet composition with a prolonged release of tamsulosin |
US8933201B2 (en) * | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
US20080033045A1 (en) * | 2006-07-07 | 2008-02-07 | Myriad Genetics, Incorporated | Treatment of psychiatric disorders |
AR062065A1 (es) | 2006-07-14 | 2008-10-15 | Ac Immune Sa | Anticuerpo humanizado |
WO2008010235A2 (en) * | 2006-07-19 | 2008-01-24 | Torrent Pharmaceuticals Limited | An improved process for the preparation of donepezil |
WO2008011161A2 (en) | 2006-07-21 | 2008-01-24 | Bridge Pharma, Inc. | Dermal anesthetic compounds |
WO2008019431A1 (en) * | 2006-08-14 | 2008-02-21 | Brc Operations Pty Limited | Method and compositions for simultaneously regulating memory and mood |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
ATE549021T1 (de) | 2006-10-27 | 2012-03-15 | Medivation Neurology Inc | Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil |
JP2010512328A (ja) | 2006-12-11 | 2010-04-22 | レビバ ファーマシューティカルズ,インコーポレーテッド | インダノン系コリンエステラーゼ阻害薬の組成物、合成および使用方法 |
EP2131828A2 (en) * | 2007-03-05 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Ampa and nmda receptor antagonists for neurodegenerative diseases |
KR20080092515A (ko) * | 2007-04-12 | 2008-10-16 | 동화약품공업주식회사 | 도네페질 중간체의 제조방법 |
ES2476605T3 (es) * | 2007-04-24 | 2014-07-15 | Shionogi & Co., Ltd. | Derivados de aminohidrotiazina sustituidos con grupos cíclicos |
US8653067B2 (en) | 2007-04-24 | 2014-02-18 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating Alzheimer's disease |
US20100130537A1 (en) * | 2007-04-26 | 2010-05-27 | Eisai R&D Management Co., Ltd | Cinnamide compounds for dementia |
KR20090130347A (ko) * | 2007-05-09 | 2009-12-22 | 화이자 인코포레이티드 | 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도 |
AR066664A1 (es) * | 2007-05-22 | 2009-09-02 | Otsuka Pharma Co Ltd | Un medicamento para tratar enfermedad de alzheimer |
NZ581834A (en) * | 2007-06-12 | 2012-06-29 | Ac Immune Sa | Humanized antibodies to amyloid beta |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
WO2009011412A2 (en) * | 2007-07-13 | 2009-01-22 | Eisai R & D Management Co., Ltd. | Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain |
DE102007037932A1 (de) | 2007-08-11 | 2009-02-12 | Alfred E. Tiefenbacher Gmbh & Co.Kg | Donepezilhydrochlorid in amorpher Form enthaltende Tablette |
US8304435B2 (en) | 2007-09-12 | 2012-11-06 | Deuteria Pharmaceuticals Inc. | Deuterium-enriched donepezil |
CN101397270B (zh) * | 2007-09-28 | 2012-03-28 | 天津和美生物技术有限公司 | 多奈哌齐盐的多晶型物及其制备和应用 |
TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
BRPI0818643A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga de placa na camada celular de gânglio retinal de um paciente, para reduzir a quantidade de placas na camada celular de gânglio retinal de um paciente, para diminuir a quantidade total de amilóide-beta solúvel na camada celular de gânglio retinal de um paciente, para evitar, tratar ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para diagnosticar uma predisposição a uma doença ocular associada com anormalidades patológicas/mudanças nos tecidos dos sistema visual, para monitorar doenças ocular mínima residual associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer a responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um paciente |
US20100297012A1 (en) * | 2007-10-05 | 2010-11-25 | Andrea Pfeifer | Humanized antibody |
JP5566004B2 (ja) | 2007-11-14 | 2014-08-06 | 株式会社Dnpファインケミカル宇都宮 | アルコキシインダノン誘導体の製造方法 |
WO2009118516A1 (en) | 2008-03-25 | 2009-10-01 | Cipla Limited | Process for the preparation of donepezil hydrochloride |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
JP5490692B2 (ja) | 2008-06-13 | 2014-05-14 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
WO2010019560A1 (en) * | 2008-08-12 | 2010-02-18 | Concert Pharmaceuticals Inc. | Deuterated derivatives of donepezil |
EP2328582A4 (en) * | 2008-09-30 | 2012-02-22 | Teikoku Pharma Usa Inc | DERPEZIL COMPOSITIONS WITH EXTENDED TRANSDERMAL DELIVERY AND METHODS OF USE |
CN102186841A (zh) * | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
US20100105916A1 (en) * | 2008-10-29 | 2010-04-29 | Sterling Biotech Limited | Processes for Preparing Donepezil |
US20110230497A1 (en) * | 2008-11-07 | 2011-09-22 | H. Lundbeck A/S | Biologically active amides |
WO2010077730A2 (en) * | 2008-12-09 | 2010-07-08 | Auspex Pharmaceutical, Inc | Indanone inhibitors of acetylcholinesterase |
US8247405B2 (en) | 2008-12-10 | 2012-08-21 | Conopco, Inc. | Skin lightening compositions with acetylcholinesterase inhibitors |
WO2010071216A1 (en) | 2008-12-17 | 2010-06-24 | Eisai R&D Management Co., Ltd. | Polymorphic crystal of donepezil and process for producing the same |
US8465770B2 (en) * | 2008-12-24 | 2013-06-18 | Synthon Bv | Low dose controlled release tablet |
EP2213278A1 (de) | 2009-01-28 | 2010-08-04 | Labtec GmbH | Pharmazeutische Zubereitung mit verbesserter Stabilität des Wirkstoffs |
JP4666093B2 (ja) * | 2009-03-13 | 2011-04-06 | ユニマテック株式会社 | ポリフルオロアルキルホスホン酸エステルの製造法 |
WO2011004705A1 (ja) * | 2009-07-10 | 2011-01-13 | ユニマテック株式会社 | ポリフルオロアルキルホスホン酸エステルおよびその製造法 |
CN102596382B (zh) * | 2009-11-04 | 2014-09-17 | 优迈特株式会社 | 聚氟烷基膦酸盐乳化剂和以该乳化剂作为有效成分的脱模剂 |
US8735423B2 (en) | 2009-11-18 | 2014-05-27 | Suven Life Sciences Limited | Bicyclic compounds as α4β2 nicotinic acetylcholine receptor ligands |
WO2011061591A1 (en) | 2009-11-18 | 2011-05-26 | Jubilant Life Sciences Limited | Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii |
RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
BR112012016201A2 (pt) | 2009-12-29 | 2017-12-19 | Suven Life Sciences Ltd | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
EA202092673A3 (ru) * | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
US20110251239A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
GR1007368B (el) | 2010-05-27 | 2011-08-02 | Alapis Α.Β.Ε.Ε., | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
FR2962335B1 (fr) | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
TR201007110A2 (tr) | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Sinerjik etki gösteren kombinasyonlar |
TR201007109A2 (tr) | 2010-08-25 | 2012-03-21 | Bi̇lgi̇ç Mahmut | Tek birim dozaj formları. |
WO2012038966A1 (en) | 2010-09-22 | 2012-03-29 | Tyche Industries Ltd. | Process for the preparation of donepezil intermediate |
JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
JP5916746B2 (ja) | 2010-11-15 | 2016-05-11 | エージンバイオ, インコーポレイテッド | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
JP5951625B2 (ja) | 2010-11-24 | 2016-07-13 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークThe Trustees Of Columbia University In The City Of New York | 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドrbp4アンタゴニスト |
JPWO2012147763A1 (ja) | 2011-04-26 | 2014-07-28 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するbace1阻害剤 |
EP2710203B1 (de) | 2011-05-16 | 2018-12-19 | Weitzer Holding GmbH | Boden- oder wandbelagsystem mit modular kombinierbaren verlegeeinheiten |
EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
AU2013245702A1 (en) | 2012-04-14 | 2014-11-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN103524515B (zh) | 2012-07-03 | 2016-07-06 | 浙江海正药业股份有限公司 | 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
CN103787954B (zh) * | 2012-10-26 | 2016-01-20 | 中国科学院上海药物研究所 | 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途 |
US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
JPWO2014076965A1 (ja) * | 2012-11-16 | 2017-01-05 | 学校法人北里研究所 | 抗原虫活性を示す1−インダン誘導体 |
EP2759536A1 (en) | 2013-01-25 | 2014-07-30 | INSA (Institut National des Sciences Appliquees) de Rouen | Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents |
CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
WO2014171434A1 (ja) | 2013-04-19 | 2014-10-23 | 国立大学法人岡山大学 | アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法 |
DK3033082T3 (da) | 2013-08-16 | 2021-09-20 | Univ Maastricht | Behandling af kognitiv svækkelse med pde4-hæmmer |
US9359315B2 (en) * | 2013-09-10 | 2016-06-07 | Arrien Pharmaceuticals Llc | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis |
CN106068256B (zh) | 2013-12-20 | 2020-10-23 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法 |
FR3018689B1 (fr) * | 2014-03-20 | 2017-04-28 | Centre Hospitalier Univ De Clermont Ferrand | Inhibiteurs de l'acetylcholinesterase d'action centrale pour la prevention et/ou le traitement des neuropathies chimio-induites et leurs symptomes, compositions, utilisations, methodes et trousse correspondantes. |
CN105753768B (zh) * | 2014-12-15 | 2020-11-27 | 北京恒瑞新霖科技有限公司 | 一种含单个氮杂环化合物的生产方法 |
TWI770525B (zh) | 2014-12-30 | 2022-07-11 | 美商瓦洛健康公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
WO2016126926A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
JP2018504431A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのチエノピリミジノン |
EP3253759A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
CN113264939A (zh) | 2015-06-19 | 2021-08-17 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法 |
CN115252586A (zh) | 2015-06-22 | 2022-11-01 | 考里安公司 | 包含难溶性治疗剂的透皮粘合剂组合物 |
CN105367483B (zh) * | 2015-11-20 | 2017-12-26 | 山东淄博新达制药有限公司 | 盐酸多奈哌齐的制备方法 |
CA3026983A1 (en) | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
CN109922796B (zh) | 2016-06-23 | 2023-04-07 | 考里安有限责任公司 | 具有亲水和疏水域的粘合剂基质和治疗剂 |
KR101829631B1 (ko) | 2016-07-20 | 2018-02-19 | 주식회사 엔솔바이오사이언스 | 신규 펩타이드 및 그 용도 |
RU2764764C2 (ru) | 2016-07-27 | 2022-01-21 | Кориум Интернэшнл, Инк. | Трансдермальные системы доставки мемантина |
EP3490541A2 (en) | 2016-07-27 | 2019-06-05 | Corium International, Inc. | Transdermal formulation and delivery method of low solubility or unstable unionized neutral drugs byin situ |
KR102424270B1 (ko) | 2016-07-27 | 2022-07-25 | 코리움, 인크. | 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템 |
US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
US10369187B2 (en) | 2017-02-09 | 2019-08-06 | Vanderbilt University | Peptide regulators of JNK family kinases |
CA3085342A1 (en) | 2017-12-13 | 2019-06-20 | Corium, Inc. | Method for depot creation during transdermal drug delivery |
WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
CN112601749B (zh) | 2018-06-19 | 2024-03-26 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法 |
SI3843702T1 (sl) | 2019-05-31 | 2023-12-29 | Technimede, Sociedade Tecnico-Medicinal, SA | Kombinacija memantina in donepezila v fiksnem odmerku s takojšnjim sproščanjem |
JP7452810B2 (ja) * | 2019-06-17 | 2024-03-19 | 東和薬品株式会社 | 固定化触媒を用いたフロー反応によるドネペジルの製造方法 |
KR20220059300A (ko) * | 2020-11-02 | 2022-05-10 | 주식회사 종근당 | 인덴 유도체 프로드럭의 산부가염 및 이의 제조방법 |
KR102451185B1 (ko) | 2021-08-05 | 2022-10-07 | 환인제약 주식회사 | 도네페질 함유 지속방출형 미립구 |
WO2023134711A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海科技大学 | 并环哌啶类化合物及其制备方法和用途 |
US20240132513A1 (en) | 2022-08-19 | 2024-04-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
WO2024161166A1 (en) | 2023-02-02 | 2024-08-08 | Universite De Mcgill | New acetylcholinesterase inhibitors and uses thereof for preventing and treating compulsive disorders and neurodegenerative disorders |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3171838A (en) * | 1961-10-10 | 1965-03-02 | Res Lab Dr C Janssen N V | Aroylalkyl and hydroxyaralkyl derivatives of 4-(n-arylalkanamido)-piperidines and related compounds |
US3454565A (en) * | 1966-10-05 | 1969-07-08 | American Cyanamid Co | Novel indanones |
US3452030A (en) * | 1966-12-12 | 1969-06-24 | Aldrich Chem Co Inc The | 4-(n-isobutyrylanilino)-1-benzylpiperidine |
US3476759A (en) * | 1967-05-02 | 1969-11-04 | Mcneilab Inc | 2- and 3-(4-piperidyl) indanes and indanols |
DE2021262A1 (de) * | 1970-04-30 | 1971-11-11 | Cassella Farbwerke Mainkur Ag | Piperazinderivate |
DE2148959C3 (de) * | 1971-09-30 | 1978-05-18 | Ordena Trudovogo Krasnogo Znameni Institut Organitscheskogo Sintesa Akademii Nauk Latvijskoj Ssr, Riga (Sowjetunion) | Verfahren zur Herstellung N-substituierter 4-Anilinopiperidine |
GB1323508A (en) * | 1971-10-06 | 1973-07-18 | Inst Organicheskogo Sinteza Ak | Method for preparation of n-substituted 4-aniline piperidines |
GB1416872A (en) | 1972-03-10 | 1975-12-10 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
DE2513136C3 (de) * | 1974-03-21 | 1981-04-30 | Anphar S.A., Madrid | N-(1-Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate |
DK141752B (da) * | 1974-07-31 | 1980-06-09 | Ciba Geigy Ag | Aalogifremgangsmåde til fremstilling af piperidiner eller salte deraf. |
JPS5152176A (zh) * | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
US4130646A (en) * | 1975-07-25 | 1978-12-19 | E. R. Squibb & Sons, Inc. | 1,2,3,4-Tetrahydro-2-((4-(phenyl)-1-piperazinyl)methyl)-1-naphthalenols and derivatives and analogs thereof |
GB1583753A (en) * | 1976-07-14 | 1981-02-04 | Science Union & Cie | Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them |
GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
GB1575310A (en) * | 1976-11-16 | 1980-09-17 | Anphar Sa | Piperidine derivatives |
BE864269A (fr) | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
ZA786426B (en) | 1977-11-25 | 1979-10-31 | Scras | New indulo(2,3-a)quinolizidines,preparation and therapeutic use |
SE7907121L (sv) * | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
EP0029707B1 (en) * | 1979-11-21 | 1984-02-01 | Kyowa Hakko Kogyo Co., Ltd | Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them |
US4254127A (en) * | 1980-04-03 | 1981-03-03 | Janssen Pharmaceutica, N.V. | 1,3-Dihydro-1-[(1-piperidinyl)alkyl]-2H-benzimidazol-2-one derivatives |
FR2484415A1 (fr) * | 1980-06-13 | 1981-12-18 | Pharmindustrie | Nouveaux derives de l'indene, procedes pour leur preparation, et leur utilisation comme medicaments |
JPS58180481A (ja) * | 1982-04-15 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
JPS5976082A (ja) * | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
JPS59112984A (ja) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | 1,4−ベンゾジアゼピン誘導体 |
FR2538388B1 (fr) * | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
US4734275A (en) | 1983-08-19 | 1988-03-29 | Research Corporation | Anti-curare agents |
SE8503054D0 (sv) * | 1985-06-19 | 1985-06-19 | Astra Laekemedel Ab | Catecholcarboxamides |
DE3541811A1 (de) * | 1985-11-27 | 1987-06-04 | Thomae Gmbh Dr K | Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
GB8601160D0 (en) | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
PH23078A (en) * | 1986-01-30 | 1989-04-10 | Ciba Geigy Ag | Substituted pyrrolidinones |
JPH0721821B2 (ja) * | 1986-07-07 | 1995-03-08 | ソニー株式会社 | 動き物体の集計装置 |
KR910006138B1 (ko) * | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
-
1988
- 1988-06-08 FI FI882716A patent/FI95572C/fi active IP Right Grant
- 1988-06-09 NZ NZ224970A patent/NZ224970A/xx unknown
- 1988-06-13 PH PH37060A patent/PH26315A/en unknown
- 1988-06-17 ZA ZA884338A patent/ZA884338B/xx unknown
- 1988-06-17 NO NO882696A patent/NO177590C/no not_active IP Right Cessation
- 1988-06-20 US US07/209,339 patent/US4895841A/en not_active Expired - Lifetime
- 1988-06-21 DK DK337988A patent/DK172337B1/da not_active IP Right Cessation
- 1988-06-21 HU HU883160A patent/HU214592B/hu unknown
- 1988-06-21 RU SU884356030A patent/RU2009128C1/ru active
- 1988-06-21 CA CA000569944A patent/CA1338808C/en not_active Expired - Lifetime
- 1988-06-21 DD DD88316988A patent/DD283377A5/de unknown
- 1988-06-22 AT AT88109924T patent/ATE134618T1/de active
- 1988-06-22 DE DE1997175093 patent/DE19775093I1/de active Pending
- 1988-06-22 AU AU18216/88A patent/AU627151B2/en not_active Expired
- 1988-06-22 DE DE3856491T patent/DE3856491T2/de not_active Expired - Lifetime
- 1988-06-22 EP EP93113146A patent/EP0579263B1/en not_active Expired - Lifetime
- 1988-06-22 AT AT93113146T patent/ATE171161T1/de not_active IP Right Cessation
- 1988-06-22 CN CN88103779A patent/CN1024547C/zh not_active Expired - Lifetime
- 1988-06-22 ES ES88109924T patent/ES2083359T3/es not_active Expired - Lifetime
- 1988-06-22 AT AT96110252T patent/ATE204862T1/de not_active IP Right Cessation
- 1988-06-22 EP EP88109924A patent/EP0296560B1/en not_active Expired - Lifetime
- 1988-06-22 EP EP01102878A patent/EP1116716A1/en not_active Withdrawn
- 1988-06-22 AT AT95104080T patent/ATE205828T1/de not_active IP Right Cessation
- 1988-06-22 SG SG1996001509A patent/SG50439A1/en unknown
- 1988-06-22 EP EP95104080A patent/EP0673927B1/en not_active Expired - Lifetime
- 1988-06-22 KR KR1019880007562A patent/KR910003618B1/ko not_active IP Right Cessation
- 1988-06-22 ES ES93113146T patent/ES2121039T3/es not_active Expired - Lifetime
- 1988-06-22 ES ES96110252T patent/ES2160747T3/es not_active Expired - Lifetime
- 1988-06-22 PT PT87783A patent/PT87783B/pt not_active IP Right Cessation
- 1988-06-22 DE DE3855028T patent/DE3855028T2/de not_active Expired - Lifetime
- 1988-06-22 DE DE3856487T patent/DE3856487T2/de not_active Expired - Lifetime
- 1988-06-22 EP EP96110252A patent/EP0742207B1/en not_active Expired - Lifetime
- 1988-06-22 JP JP63153852A patent/JP2578475B2/ja not_active Expired - Lifetime
- 1988-06-22 DE DE3856251T patent/DE3856251T2/de not_active Expired - Lifetime
- 1988-06-22 ES ES95104080T patent/ES2164720T3/es not_active Expired - Lifetime
-
1989
- 1989-10-18 US US07/423,349 patent/US5100901A/en not_active Expired - Lifetime
-
1992
- 1992-11-10 CN CN92112982A patent/CN1034015C/zh not_active Expired - Lifetime
- 1992-11-12 CN CN92112995A patent/CN1038839C/zh not_active Expired - Lifetime
-
1994
- 1994-11-25 JP JP6291169A patent/JP2733203B2/ja not_active Expired - Lifetime
-
1995
- 1995-04-24 CA CA000616996A patent/CA1340192C/en not_active Expired - Fee Related
- 1995-05-04 HU HU95P/P00123P patent/HU211165A9/hu unknown
- 1995-05-04 HU HU95P/P00122P patent/HU211144A9/hu unknown
- 1995-06-09 FI FI952850A patent/FI102534B1/fi active
-
1996
- 1996-02-29 GR GR950402584T patent/GR3019142T3/el unknown
- 1996-07-04 FI FI962753A patent/FI103969B1/fi active
- 1996-10-03 DK DK199601082A patent/DK175246B1/da not_active IP Right Cessation
- 1996-10-03 DK DK199601083A patent/DK175717B1/da not_active IP Right Cessation
- 1996-12-19 HK HK216396A patent/HK216396A/xx not_active IP Right Cessation
-
1997
- 1997-05-16 CY CY194097A patent/CY1940A/xx unknown
- 1997-07-11 JP JP09186306A patent/JP3078244B2/ja not_active Expired - Lifetime
-
1998
- 1998-03-06 LU LU90221C patent/LU90221I2/fr unknown
- 1998-05-12 NO NO1998015C patent/NO1998015I1/no unknown
-
2001
- 2001-09-06 GR GR20010401406T patent/GR3036553T3/el not_active IP Right Cessation
- 2001-12-14 CY CY0100044A patent/CY2349B1/xx unknown
- 2001-12-14 CY CY0100045A patent/CY2350B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO177590C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive cykliske aminforbindelser | |
FR2651229B1 (fr) | Nouveaux derives d'amino-acides, leur procede de preparation et leur application therapeutique. | |
NO159018C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive disubstituerte polymetyleniminer. | |
DK702788A (da) | Thioformamidderivater og farmaceutisk acceptable salte deraf, deres fremstilling og anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired | ||
LC4 | Limitation of patent rights - b3 (par. 39b patent act) | ||
SPCX | Expiry of an spc |
Free format text: PRODUCT NAME: DONEPEZIL; NAT. REGISTRATION NO/DATE: 96-3400 19989319; FIRST REGISTRATION: GB 10555/0006 19970214 Spc suppl protection certif: 1998015 Filing date: 19970214 Extension date: 20120214 |